Short answer
Praxis Precision Medicines, Inc. (PRAX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1). Fiscal results announced for quarter ended June 30, 2026.
Praxis Precision Medicines, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal results announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing detailed financial results and management commentary
- Investor focus: quarterly performance, cash position and clinical-program funding implications
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation for investor and analyst meetings as of August 6, 2026
- Presentation available on Praxis’s investor website and furnished as Exhibit 99.2
- Investor materials may contain updated strategy, pipeline, or clinical information requiring review
- Disclosure furnished under Regulation FD, limiting Section 18 Exchange Act liability for the presentation
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss $83.7M, or $2.87 per share, versus $71.1M and $3.31 in Q2 2025
- Cash and investments $1.4B, up from $926.1M, extending operations into 2028
- Ulixacaltamide PDUFA January 29, 2027, with no major FDA safety or efficacy concerns and no advisory committee planned
- Relutrigine PDUFA December 27, 2026, after review extension for major amendment, with no major FDA concerns or advisory committee planned
- Vormatrigine missed its primary POWER1 endpoint, putting planned POWER2 and POWER3 studies in Q4 2026 under heightened scrutiny
Item EX-99.2 · Exhibit EX-99.2
- Four late-stage CNS assets, including two PDUFA dates: relutrigine December 27, 2026 and ulixacaltamide January 2027
- Portfolio peak-sales potential above $20B, led by ulixacaltamide above $10B and relutrigine above $5B
- Cash runway projected into 2028, supporting development and potential launches across four CNS products
- Ulixacaltamide Phase 3 program met endpoints, with launch preparations underway for essential tremor in early 2027
- Relutrigine Emerald topline data expected in Q4 2026, creating a near-term catalyst beyond the December FDA decision
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Praxis Precision Medicines, Inc. 8-K filings
Get the next PRAX 8-K as it lands
Follow PRAX for push alerts, or ask the research agent what this filing means.